ARS Pharmaceuticals (SPRY) Short-term Investments (2022 - 2026)

ARS Pharmaceuticals has reported Short-term Investments for 5 years, with the latest figure at $176.6 million in Q1 2026.

• Quarterly Short-term Investments fell 25.11% year-over-year to $176.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $176.6 million (down 25.11% YoY) and the FY2025 annual result came in at $203.7 million, down 22.62% from the prior year.
• Short-term Investments eased to $176.6 million in Q1 2026 per SPRY's latest filing, from $203.7 million in the prior quarter.
• Over five years, Short-term Investments peaked at $263.2 million in Q4 2024 and troughed at $19.9 million in Q1 2022.
• A 5-year average of $155.7 million and a median of $176.6 million in 2026 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2026: Short-term Investments jumped 789.75% in 2023, then dropped 25.11% in 2026.
• Over 5 years, Short-term Investments stood at $63.9 million in 2022, then surged by 146.45% to $157.4 million in 2023, then soared by 67.23% to $263.2 million in 2024, then retreated by 22.62% to $203.7 million in 2025, then dropped by 13.27% to $176.6 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $176.6 million, $203.7 million, and $228.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.